Stephens, J., Shrikrishnapalasuriyar, N., Shaikh, A., Ruslan, A. M., Sharaf, G., Udiawar, M., & Price, D. E. (2020). Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14(3), pp. 237-239. doi:10.1016/j.dsx.2020.03.007

Stephens, Jeffrey, Natasha Shrikrishnapalasuriyar, Ayesha Shaikh, Aliya Mohd Ruslan, Giselle Sharaf, Maneesh Udiawar, and David E. Price. "Dapagliflozin Is Associated With Improved Glycaemic Control and Weight Reduction At 44 Months of Follow-up in a Secondary Care Diabetes Clinic in the UK." Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14, no. 3 (2020): 237-239.

Stephens, Jeffrey, et al. "Dapagliflozin Is Associated With Improved Glycaemic Control and Weight Reduction At 44 Months of Follow-up in a Secondary Care Diabetes Clinic in the UK." Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14.3 (2020): 237-239.